Clinical Trials


A Study of T-20 in HIV-Positive Adults

This study has been completed

Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service Identifier

First received: November 2, 1999
Last updated: June 23, 2005
Last Verified: April 1999
History of Changes


The purpose of this study is to see if it is safe and effective to give T-20 to HIV-positive adults. T-20 is an anti-HIV drug.

Condition Intervention Phase
HIV Infections

Drug : Enfuvirtide
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase II Evaluation of the Safety, Plasma Pharmacokinetics, and Antiviral Activity of T-20 Administered to HIV-1 Positive Adults By Continuous Subcutaneous Infusion or Subcutaneous Injection

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Enrollment: 78

Detailed Description:

Patients are randomly placed into 1 of 6 groups: 4 dose levels of T-20 are given by subcutaneous infusion and 2 by subcutaneous injection. The entire study lasts 7 weeks; including a 2-week screening period, followed by 28 days of treatment and 1 week of follow-up.



Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria
Concurrent Medication:

  • Any antiretroviral agent, provided the regimen has not changed within 6 weeks of the screening visit.
  • Antibiotics for bacterial infections.
  • Prophylactic medications for P. carinii pneumonia and for M. avium, including azithromycin.
  • Medications for symptomatic treatment such as antipyretics, analgesics, and antiemetics.

  • Patients must have:
    HIV-1 seropositive status.
    Exclusion Criteria
    Co-existing Condition:
    Patients with the following symptoms or conditions are excluded:
    Concurrent neoplasm (except for basal cell carcinoma of the skin, in situ carcinoma of the cervix, and non-disseminated stable Kaposi's sarcoma).
    Concurrent Medication:
  • Patients must not be taking any concurrent antiretroviral therapy (for at least 2 weeks prior to baseline) or the patient is to be on a stable antiretroviral regimen which has not changed for at least 6 weeks prior to baseline.
  • Treatment with any of the following:
  • immunomodulators, biological response modifiers, chemotherapy that cannot be discontinued for the duration of the study, astemizole, terfenadine, cisapride, triazolam, midazolam, rifampin, clarithromycin, or an investigational drug within 30 days prior to the initial visit.

  • Patients with the following prior conditions are excluded:
  • Evidence of active opportunistic infections, or unexplained temperature greater than or equal to 38.5 Celsius for 7 consecutive days within 30 days prior to screening visit.
  • Chronic diarrhea (defined as greater than 3 liquid stools per day which persists for 15 days) within 30 days prior to screening visit.
  • Diagnosis of hemophilia or other clotting disorders.

  • Prior Medication:
  • Prior treatment with an HIV vaccine.
Prior Treatment:
Major organ allograft.
Risk Behavior:
Evidence of substance abuse or addiction that, in the opinion of the investigator, may interfere with the patient's ability to comply with the dosing schedule and protocol evaluations.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00002228


United States, Alabama
Univ of Alabama at Birmingham / 1917 AIDS O/P Cln
Birmingham, Alabama, United States, 35294
United States, California
UCLA School of Medicine / Ctr for Research and Education
Los Angeles, California, United States, 900951793
San Francisco Gen Hosp
San Francisco, California, United States, 94110
Quest Clinical Research
San Francisco, California, United States, 94115
United States, Florida
IDC Research Initiative
Altamonte Springs, Florida, United States, 32701
United States, Illinois
Northwestern Univ / Infect Dis Div / Pasavant Pav 828
Chicago, Illinois, United States, 60611
United States, Maryland
Johns Hopkins Hosp
Baltimore, Maryland, United States, 21287
United States, Massachusetts
CRI of New England
Brookline, Massachusetts, United States, 02445
United States, New York
NYU Med Ctr / C & D Building
New York, New York, United States, 10016
United States, North Carolina
Univ North Carolina at Chapel Hill / Dept of Medicine
Chapel Hill, North Carolina, United States, 27599
United States, Texas
Univ of Texas / Thomas Street Clinic
Houston, Texas, United States, 77030

Sponsors and Collaborators



Study Chair: Sam Hopkins
More Information

More Information

Responsible Party: Trimeris Identifier: NCT00002228   History of Changes  
Other Study ID Numbers: 295A  
Study First Received: November 2, 1999  
Last Updated: June 23, 2005  

Keywords provided by NIH AIDS Clinical Trials Information Service:

Injections, Subcutaneous
Anti-HIV Agents
peptide T20

Additional relevant MeSH terms:
HIV Infections
Enfuvirtide processed this data on July 19, 2018
This information is provided by